

**Table 1.1.3: Top 25 and Musculoskeletal Related Conditions, Diseases and Research Areas Funded by NIH, 2010-2014**

	Research Dollars (in millions/ rounded)							Funding	
	FY 2010 Actual	FY 2010 Actual	FY 2011 Actual	FY 2012 Actual	FY 2013 Actual	FY 2014	Total 2010-	Ranking 2010-	FY 2015
	(Non-ARRA)	(ARRA) [1]				Estimated	2014	2014 [2]	Estimated
Clinical Research	\$10,720	\$1,540	\$10,503	\$10,951	\$10,604	\$10,928	\$55,246	1	\$10,928
Genetics	\$7,473	\$1,440	\$7,223	\$7,632	\$7,144	\$7,328	\$38,240	2	\$7,330
Prevention	\$5,983	\$849	\$5,929	\$5,924	\$6,686	\$6,853	\$32,224	3	\$6,853
Biotechnology	\$5,682	\$1,203	\$5,823	\$6,089	\$5,698	\$5,845	\$30,340	4	\$5,845
Cancer	\$5,823	\$803	\$5,448	\$5,621	\$5,274	\$5,418	\$28,387	5	\$5,418
Neurosciences	\$5,515	\$794	\$5,548	\$5,618	\$5,340	\$5,474	\$28,289	6	\$5,477
Infectious Diseases	\$3,890	\$568	\$3,883	\$3,867	\$4,887	\$5,015	\$22,110	7	\$5,015
Brain Disorders	\$3,847	\$619	\$3,864	\$3,968	\$3,708	\$3,796	\$19,802	8	\$3,799
Women's Health [3]	\$3,691	\$449	\$3,891	\$3,833	\$3,745	\$3,845	\$19,454	9	\$3,845
Behavioral and Social Science	\$3,526	\$603	\$3,573	\$3,682	\$3,535	\$3,616	\$18,535	10	\$3,616
Bioengineering	\$3,166	\$760	\$3,303	\$3,498	\$3,234	\$3,318	\$17,279	11	\$3,318
Pediatric	\$3,286	\$479	\$3,277	\$3,612	\$3,266	\$3,339	\$17,259	12	\$3,339
Clinical Trials	\$3,286	\$356	\$3,093	\$3,208	\$3,155	\$3,237	\$16,335	13	\$3,237
HIV/AIDS [4]	\$3,085	\$322	\$3,059	\$3,074	\$2,898	\$2,978	\$15,416	14	\$3,005
Rare Diseases	+	+	\$3,527	\$3,623	\$3,456	\$3,553	\$14,159	15	\$3,553
Health Disparities [3]	\$2,728	\$351	\$2,718	\$2,740	\$2,722	\$2,794	\$14,053	16	\$2,794
Aging	\$2,517	\$443	\$2,572	\$2,593	\$2,429	\$2,494	\$13,048	17	\$2,494
Minority Health [3]	\$2,526	\$312	\$2,504	\$2,487	\$2,428	\$2,493	\$12,750	18	\$2,493
Human Genome	\$1,904	\$598	\$1,907	\$2,271	\$2,473	\$2,538	\$11,691	19	\$2,538
Mental Health	\$2,246	\$334	\$2,275	\$2,287	\$2,174	\$2,215	\$11,531	20	\$2,215
Cardiovascular	\$2,144	\$398	\$2,049	\$2,040	\$1,964	\$2,015	\$10,610	21	\$2,015
Emerging Infectious Diseases	\$2,118	\$350	\$2,190	\$2,153	\$1,804	\$1,853	\$10,468	22	\$1,853
Biodefense [5]	\$1,794	\$221	\$1,803	\$1,791	\$1,692	\$1,741	\$9,042	23	\$1,768
Immunization	\$1,798	\$231	\$1,756	\$1,733	\$1,656	\$1,699	\$8,873	24	\$1,699
Vaccine Related	\$1,737	\$222	\$1,717	\$1,691	\$1,608	\$1,649	\$8,624	25	\$1,649
<b>Musculoskeletal Related Conditions</b>									
Arthritis	\$249	\$59	\$231	\$258	\$231	\$237	\$1,265	89	\$237
Fibromyalgia	\$9	\$0	\$11	\$13	\$11	\$11	\$55	211	\$11
Injury - Childhood Injuries	\$36	\$3	\$33	\$37	\$37	\$38	\$184	162	\$38
Injury - Unintentional Childhood Injury	\$22	\$1	\$20	\$22	\$20	\$21	\$106	189	\$21
Injury (total) Accidents/Adverse Effects	\$372	\$46	\$356	\$366	\$367	\$376	\$1,883	70	\$376
Lupus	\$112	\$15	\$106	\$108	\$92	\$95	\$528	124	\$95
Osteogenesis Imperfecta	\$8	\$4	\$9	\$9	\$8	\$8	\$46	216	\$8
Osteoporosis	\$181	\$23	\$179	\$181	\$164	\$168	\$896	105	\$168
Paget's Disease	\$1	\$0	\$1	\$1	\$0	-	\$3	236	-
Scleroderma	\$19	\$2	\$25	\$24	\$21	\$21	\$112	185	\$21
Spina Bifida	\$12	\$6	\$11	\$12	\$10	\$10	\$61	206	\$10
Temporomandibular Muscle/Joint Disorder (TMJD)	\$16	\$1	\$18	\$21	\$19	\$19	\$94	195	\$19

[1] Separate columns are used to distinguish FY 2009 and FY 2010 actual support funded from American Recovery & Reinvestment Act (ARRA) accounts from projects funded by regular annual NIH appropriations.

[2] Total condition, diseases, and research areas in ranking was 237.

[3] Reporting for this category does not follow the standard RCDC process. This category assigns project funding according to populations tracked by gender or ethnicity. The databases used to track gender/ethnicity are complex and not currently compatible with the RCDC system.

[4] The total for AIDS research includes both extramural and intramural research (including research management and support, Management Fund, and Service & Supply Fund), buildings and facilities, research training, and program evaluation, as well as research on the many HIV-associated co-infections and co-morbidities, including TB, hepatitis C, and HIV-associated cancers. It also includes all of the basic science underlying this research. Other RCDC categories are not reported this way; thus the total for AIDS-related research is not comparable to spending reported for other RCDC diseases.

[5] Reporting for this category does not follow the standard RCDC process. The total amount reported is consistent with reporting requirements for this category to the U.S. Office of Management & Budget (OMB). The project listing does not include non-project or other support costs associated with the annual total for this category. Additional information on this category is available at <http://www.niaid.nih.gov/topics/biodefenselated/pages/default.aspx>.

Source: National Institutes of Health. Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC). [http://report.nih.gov/categorical\\_spending.aspx](http://report.nih.gov/categorical_spending.aspx). Accessed June 25, 2014